Inhibiting toxic aggregation of amyloidogenic proteins: A therapeutic strategy for protein misfolding diseases

Biochimica et Biophysica Acta - General Subjects

Volumn 1830, Issue 10, 2013, Pages 4860-4871

  Cheng, Biao ^a   Gong, Hao ^a   Xiao, Hongwen ^b   Petersen, Robert B ^c   Zheng, Ling ^d   Huang, Kun ^a,e  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b CHINA INSTITUTE OF ATOMIC ENERGY   (China)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

^d WUHAN UNIVERSITY   (China)

^e Wuhan Institute of Biotechnology   (China)

Author keywords

Amyloid; Cytotoxicity; Inhibitor; Polyphenols; Protein misfolding disease

Indexed keywords

A 705253; ALPHA SYNUCLEIN; AMYLIN; AMYLOID BETA PROTEIN; AMYLOID PROTEIN; BAICALEIN; CAFFEIC ACID; CATECHIN; CHLOROGENIC ACID; COUMARIN DERIVATIVE; CURCUMIN; EPIGALLOCATECHIN GALLATE; FUROSEMIDE; KAEMPFEROL; MORIN; MYRICETIN; OLEUROPEIN; PEPTIDE DERIVATIVE; PHENOLSULFONPHTHALEIN; POLYPHENOL DERIVATIVE; PRION PROTEIN; PROCYANIDIN; PROTEIN INHIBITOR; QUERCETIN; REACTIVE OXYGEN METABOLITE; RESVERATROL; SALVIANOLIC ACID B; SILIBININ; SOLANEZUMAB; TAFAMIDIS; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; ANTIDIABETIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; BIOAVAILABILITY; CHEMICAL STRUCTURE; CLINICAL TRIAL (TOPIC); COFFEE; CYTOTOXICITY; DIET THERAPY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG EFFICACY; ENDOPLASMIC RETICULUM STRESS; FAMILIAL AMYLOID POLYNEUROPATHY; FOOD INTAKE; HUMAN; HUNTINGTON CHOREA; IMMUNOTHERAPY; IN VIVO STUDY; LIPID MEMBRANE; MAXIMUM PLASMA CONCENTRATION; MEMBRANE PERMEABILITY; MOLECULAR RECOGNITION; NEUROPATHY; NEUROPROTECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN ASSEMBLY; PROTEIN BINDING; PROTEIN DEFICIENCY; PROTEIN METHYLATION; PROTEIN MISFOLDING DISEASE; REVIEW; RISK REDUCTION; STRUCTURE ACTIVITY RELATION; WINE;

(-)-EPIGALLOCATECHIN 3-GALLATE; AΒ; ACETYLCHOLINESTERASE; ACHE; AD; AIF; ALZHEIMER'S DISEASE; AMYLOID; AMYLOID-BETA; APOPTOSIS INDUCE FACTOR; BBB; BLOOD BRAIN BARRIER; C/EBP HOMOLOGOUS PROTEIN; CA; CAFFEIC ACID; CD; CENTRAL NERVOUS SYSTEM; CGA; CHLOROGENIC ACID; CHOP; CIRCULAR DICHROISM; CNS; CYTOTOXICITY; EGCG; ENDOPLASMIC RETICULUM; ER; FAMILIAL AMYLOID POLYNEUROPATHY; FAP; HD; HTT; HUNTINGTIN; HUNTINGTON DISEASE; INHIBITOR; PARKINSON'S DISEASE; PD; PHOTO-INDUCED CROSS-LINKING OF UNMODIFIED PROTEINS; PICUP; PMDS; POLYPHENOLS; PROTEIN MISFOLDING DISEASE; PROTEIN MISFOLDING DISEASES; REACTIVE OXYGEN SPECIES; ROS; SAR; STRUCTURE-ACTIVITY RELATIONSHIPS; T2DM; TYPE 2 DIABETES MELLITUS;

AMYLOIDOGENIC PROTEINS; HUMANS; OXIDATIVE STRESS; PROTEIN FOLDING; PROTEOSTASIS DEFICIENCIES;

EID: 84884769320     PISSN: 03044165     EISSN: 18728006     Source Type: Journal    
DOI: 10.1016/j.bbagen.2013.06.029     Document Type: Review

References (187)

1. B. Caughey, and P.T. Lansbury Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders Annu. Rev. Neurosci. 26 2003 267 298 (Pubitemid 37064935)
2. M.G. Savelieff, S. Lee, Y. Liu, and M.H. Lim Untangling amyloid-beta, tau, and metals in Alzheimer's disease ACS Chem. Biol. 8 2013 856 865
3. S. Mondragon-Rodriguez, G. Perry, X. Zhu, and J. Boehm Amyloid beta and tau proteins as therapeutic targets for Alzheimer's disease treatment: rethinking the current strategy Int. J. Alzheimers Dis. 2012 2012 630182
4. J.Q. Trojanowski, and V.M. Lee Aggregation of neurofilament and alpha-synuclein proteins in Lewy bodies: implications for the pathogenesis of Parkinson disease and Lewy body dementia Arch. Neurol. 55 1998 151 152
5. M.B. Pepys, P.N. Hawkins, D.R. Booth, D.M. Vigushin, G.A. Tennent, A.K. Soutar, N. Totty, O. Nguyen, C.C. Blake, and C.J. Terry Human lysozyme gene mutations cause hereditary systemic amyloidosis Nature 362 1993 553 557 (Pubitemid 23113032)
6. P. Westermark, C. Wernstedt, E. Wilander, D.W. Hayden, T.D. O'Brien, and K.H. Johnson Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islet cells Proc. Natl. Acad. Sci. U. S. A. 84 1987 3881 3885 (Pubitemid 17088383)
7. M. DiFiglia, E. Sapp, K.O. Chase, S.W. Davies, G.P. Bates, J.P. Vonsattel, and N. Aronin Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain Science 277 1997 1990 1993 (Pubitemid 27449140)
8. H.T. Orr, and H.Y. Zoghbi Trinucleotide repeat disorders Annu. Rev. Neurosci. 30 2007 575 621 (Pubitemid 47218768)
9. J.W. Kelly Alternative conformations of amyloidogenic proteins govern their behavior Curr. Opin. Struct. Biol. 6 1996 11 17 (Pubitemid 26073939)
10. J.T. Jarrett, and P.T. Lansbury Jr. Seeding "one-dimensional crystallization" of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Cell 73 1993 1055 1058 (Pubitemid 23180480)
11. T.P. Knowles, C.A. Waudby, G.L. Devlin, S.I. Cohen, A. Aguzzi, M. Vendruscolo, E.M. Terentjev, M.E. Welland, and C.M. Dobson An analytical solution to the kinetics of breakable filament assembly Science 326 2009 1533 1537
12. F. Meersman, and C.M. Dobson Probing the pressure-temperature stability of amyloid fibrils provides new insights into their molecular properties Biochim. Biophys. Acta 1764 2006 452 460
13. L.A. Potempa, B.M. Kubak, and H. Gewurz Effect of divalent metal ions and pH upon the binding reactivity of human serum amyloid P component, a C-reactive protein homologue, for zymosan. Preferential reactivity in the presence of copper and acidic pH J. Biol. Chem. 260 1985 12142 12147 (Pubitemid 16228378)
14. Y. Li, J. Yan, X. Zhang, and K. Huang Disulfide bonds in amyloidogenesis diseases related proteins Proteins 2013 10.1002/prot.24338
15. F. Rousseau, J. Schymkowitz, and L. Serrano Protein aggregation and amyloidosis: confusion of the kinds? Curr. Opin. Struct. Biol. 16 2006 118 126 (Pubitemid 43221880)
16. M.D. Kirkitadze, M.M. Condron, and D.B. Teplow Identification and characterization of key kinetic intermediates in amyloid beta-protein fibrillogenesis J. Mol. Biol. 312 2001 1103 1119 (Pubitemid 32980329)
17. M. Zhu, J. Li, and A.L. Fink The association of alpha-synuclein with membranes affects bilayer structure, stability, and fibril formation J. Biol. Chem. 278 2003 40186 40197 (Pubitemid 37248587)
18. J.D. Knight, J.A. Hebda, and A.D. Miranker Conserved and cooperative assembly of membrane-bound alpha-helical states of islet amyloid polypeptide Biochemistry 45 2006 9496 9508 (Pubitemid 44223253)
19. G. Liu, A. Prabhakar, D. Aucoin, M. Simon, S. Sparks, K.J. Robbins, A. Sheen, S.A. Petty, and N.D. Lazo Mechanistic studies of peptide self-assembly: transient alpha-helices to stable beta-sheets J. Am. Chem. Soc. 132 2010 18223 18232
20. A. Abedini, and D.P. Raleigh A critical assessment of the role of helical intermediates in amyloid formation by natively unfolded proteins and polypeptides Protein Eng. Des. Sel. 22 2009 453 459
21. S. Sparks, G. Liu, K.J. Robbins, and N.D. Lazo Curcumin modulates the self-assembly of the islet amyloid polypeptide by disassembling alpha-helix Biochem. Biophys. Res. Commun. 422 2012 551 555
22. J.D. Harper, and P.T. Lansbury Jr. Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins Annu. Rev. Biochem. 66 1997 385 407 (Pubitemid 27274662)
23. M. Sunde, and C.C. Blake From the globular to the fibrous state: protein structure and structural conversion in amyloid formation Q. Rev. Biophys. 31 1998 1 39 (Pubitemid 28379176)
24. C.M. Dobson Protein misfolding, evolution and disease Trends Biochem. Sci. 24 1999 329 332 (Pubitemid 29421804)
25. E. Gazit A possible role for pi-stacking in the self-assembly of amyloid fibrils FASEB J. 16 2002 77 83 (Pubitemid 34027953)
26. L.O. Tjernberg, J. Naslund, F. Lindqvist, J. Johansson, A.R. Karlstrom, J. Thyberg, L. Terenius, and C. Nordstedt Arrest of beta-amyloid fibril formation by a pentapeptide ligand J. Biol. Chem. 271 1996 8545 8548 (Pubitemid 26123269)
27. C.V. Sindelar, Z.S. Hendsch, and B. Tidor Effects of salt bridges on protein structure and design Protein Sci. 7 1998 1898 1914 (Pubitemid 28432431)
28. C. Hilbich, B. Kisters-Woike, J. Reed, C.L. Masters, and K. Beyreuther Substitutions of hydrophobic amino acids reduce the amyloidogenicity of Alzheimer's disease beta A4 peptides J. Mol. Biol. 228 1992 460 473 (Pubitemid 23007569)
29. S. Sinha, D.H. Lopes, and G. Bitan A key role for lysine residues in amyloid beta-protein folding, assembly, and toxicity ACS Chem. Neurosci. 3 2012 473 481
30. J. McLaurin, and A. Chakrabartty Characterization of the interactions of Alzheimer beta-amyloid peptides with phospholipid membranes Eur. J. Biochem. 245 1997 355 363 (Pubitemid 27171258)
31. M. Lindgren, and P. Hammarstrom Amyloid oligomers: spectroscopic characterization of amyloidogenic protein states FEBS J. 277 2010 1380 1388
32. S.A. Jayasinghe, and R. Langen Membrane interaction of islet amyloid polypeptide Biochim. Biophys. Acta 1768 2007 2002 2009 (Pubitemid 47125849)
33. Z. Oren, and Y. Shai Mode of action of linear amphipathic alpha-helical antimicrobial peptides Biopolymers 47 1998 451 463
34. E. Ahmad, A. Ahmad, S. Singh, M. Arshad, A.H. Khan, and R.H. Khan A mechanistic approach for islet amyloid polypeptide aggregation to develop anti-amyloidogenic agents for type-2 diabetes Biochimie 93 2011 793 805
35. E. Gazit, A. Boman, H.G. Boman, and Y. Shai Interaction of the mammalian antibacterial peptide cecropin P1 with phospholipid vesicles Biochemistry 34 1995 11479 11488
36. Y. Pouny, D. Rapaport, A. Mor, P. Nicolas, and Y. Shai Interaction of antimicrobial dermaseptin and its fluorescently labeled analogues with phospholipid membranes Biochemistry 31 1992 12416 12423 (Pubitemid 23163118)
37. M.P. Mattson, and Y. Goodman Different amyloidogenic peptides share a similar mechanism of neurotoxicity involving reactive oxygen species and calcium Brain Res. 676 1995 219 224
38. B.J. Tabner, S. Turnbull, O. El-Agnaf, and D. Allsop Production of reactive oxygen species from aggregating proteins implicated in Alzheimer's disease, Parkinson's disease and other neurodegenerative diseases Curr. Top. Med. Chem. 1 2001 507 517
39. X. Huang, C.S. Atwood, M.A. Hartshorn, G. Multhaup, L.E. Goldstein, R.C. Scarpa, M.P. Cuajungco, D.N. Gray, J. Lim, R.D. Moir, R.E. Tanzi, and A.I. Bush The A beta peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction Biochemistry 38 1999 7609 7616 (Pubitemid 29289332)
40. S. Turnbull, B.J. Tabner, O.M. El-Agnaf, S. Moore, Y. Davies, and D. Allsop Alpha-synuclein implicated in Parkinson's disease catalyses the formation of hydrogen peroxide in vitro Free Radic. Biol. Med. 30 2001 1163 1170 (Pubitemid 32441842)
41. S. Turnbull, B.J. Tabner, D.R. Brown, and D. Allsop Copper-dependent generation of hydrogen peroxide from the toxic prion protein fragment PrP106-126 Neurosci. Lett. 336 2003 159 162 (Pubitemid 36044603)
42. H. Shoval, L. Weiner, E. Gazit, M. Levy, I. Pinchuk, and D. Lichtenberg Polyphenol-induced dissociation of various amyloid fibrils results in a methionine-independent formation of ROS Biochim. Biophys. Acta 1784 2008 1570 1577
43. D. Allsop, J. Mayes, S. Moore, A. Masad, and B.J. Tabner Metal-dependent generation of reactive oxygen species from amyloid proteins implicated in neurodegenerative disease Biochem. Soc. Trans. 36 2008 1293 1298
44. H. Gong, X. Zhang, B. Cheng, Y. Sun, C. Li, T. Li, L. Zheng, and K. Huang Bisphenol A accelerates toxic amyloid formation of human islet amyloid polypeptide: a possible link between bisphenol A exposure and type 2 diabetes PLoS One 8 2013 e54198
45. C. Wang, L. Liu, L. Zhang, Y. Peng, and F. Zhou Redox reactions of the alpha-synuclein-Cu(2 +) complex and their effects on neuronal cell viability Biochemistry 49 2010 8134 8142
46. Y. Peng, C. Wang, H.H. Xu, Y.N. Liu, and F. Zhou Binding of alpha-synuclein with Fe(III) and with Fe(II) and biological implications of the resultant complexes J. Inorg. Biochem. 104 2010 365 370
47. A. Nunomura, R.J. Castellani, X. Zhu, P.I. Moreira, G. Perry, and M.A. Smith Involvement of oxidative stress in Alzheimer disease J. Neuropathol. Exp. Neurol. 65 2006 631 641 (Pubitemid 44297254)
48. M. Nakamura, N. Shishido, A. Nunomura, M.A. Smith, G. Perry, Y. Hayashi, K. Nakayama, and T. Hayashi Three histidine residues of amyloid-beta peptide control the redox activity of copper and iron Biochemistry 46 2007 12737 12743 (Pubitemid 350064223)
49. N. Ansari, and F. Khodagholi Molecular mechanism aspect of ER stress in Alzheimer's disease: current approaches and future strategies Curr. Drug Targets 14 2013 114 122
50. G. Mercado, P. Valdes, and C. Hetz An ERcentric view of Parkinson's disease Trends Mol. Med. 19 2013 165 175
51. C.J. Huang, L. Haataja, T. Gurlo, A.E. Butler, X. Wu, W.C. Soeller, and P.C. Butler Induction of endoplasmic reticulum stress-induced beta-cell apoptosis and accumulation of polyubiquitinated proteins by human islet amyloid polypeptide Am. J. Physiol. Endocrinol. Metab. 293 2007 E1656 1662
52. T. Umeda, T. Tomiyama, N. Sakama, S. Tanaka, M.P. Lambert, W.L. Klein, and H. Mori Intraneuronal amyloid beta oligomers cause cell death via endoplasmic reticulum stress, endosomal/lysosomal leakage, and mitochondrial dysfunction in vivo J. Neurosci. Res. 89 2011 1031 1042
53. R. Quiroz-Baez, P. Ferrera, R. Rosendo-Gutierrez, J. Moran, F. Bermudez-Rattoni, and C. Arias Caspase-12 activation is involved in amyloid-beta protein-induced synaptic toxicity J. Alzheimers Dis. 26 2011 467 476
54. E. Ferreiro, I. Baldeiras, I.L. Ferreira, R.O. Costa, A.C. Rego, C.F. Pereira, and C.R. Oliveira Mitochondrial- and endoplasmic reticulum-associated oxidative stress in Alzheimer's disease: from pathogenesis to biomarkers Int. J. Cell Biol. 2012 2012 735206
55. X.L. Li, T. Chen, Y.S. Wong, G. Xu, R.R. Fan, H.L. Zhao, and J.C. Chan Involvement of mitochondrial dysfunction in human islet amyloid polypeptide-induced apoptosis in INS-1E pancreatic beta cells: an effect attenuated by phycocyanin Int. J. Biochem. Cell Biol. 43 2011 525 534
56. T. Cali, D. Ottolini, and M. Brini Mitochondria, calcium, and endoplasmic reticulum stress in Parkinson's disease Biofactors 37 2011 228 240
57. M.J. Hsu, J.R. Sheu, C.H. Lin, M.Y. Shen, and C.Y. Hsu Mitochondrial mechanisms in amyloid beta peptide-induced cerebrovascular degeneration Biochim. Biophys. Acta 1800 2010 290 296
58. M. Hashimoto, E. Rockenstein, L. Crews, and E. Masliah Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer's and Parkinson's diseases Neuromolecular Med. 4 2003 21 36
59. S.M. Cardoso, S. Santos, R.H. Swerdlow, and C.R. Oliveira Functional mitochondria are required for amyloid beta-mediated neurotoxicity FASEB J. 15 2001 1439 1441
60. C.P. Ferri, R. Sousa, E. Albanese, W.S. Ribeiro, and M. Honyashiki World Alzheimer Report 2009 2009 Alzheimer's Disease International
61. Global Burden of Disease Diabetes Mellitus 2008 World Health Organization Geneva
62. L.M. Sanchez Perera, L. Varcalcel, A. Escobar, and M. Noa Polyphenol and phytosterol composition in an antibacterial extract from Rhizophora mangle L. bark J. Herb. Pharmacother. 7 2007 107 128
63. C. Wu, H. Lei, Z. Wang, W. Zhang, and Y. Duan Phenol red interacts with the protofibril-like oligomers of an amyloidogenic hexapeptide NFGAIL through both hydrophobic and aromatic contacts Biophys. J. 91 2006 3664 3672 (Pubitemid 44788309)
64. F.F. Liu, X.Y. Dong, L. He, A.P. Middelberg, and Y. Sun Molecular insight into conformational transition of amyloid beta-peptide 42 inhibited by (-)-epigallocatechin-3-gallate probed by molecular simulations J. Phys. Chem. B 115 2011 11879 11887
65. E. Herczenik, and M.F. Gebbink Molecular and cellular aspects of protein misfolding and disease FASEB J. 22 2008 2115 2133 (Pubitemid 351948631)
66. D.Y. Choi, Y.J. Lee, J.T. Hong, and H.J. Lee Antioxidant properties of natural polyphenols and their therapeutic potentials for Alzheimer's disease Brain Res. Bull. 87 2012 144 153
67. O. Weinreb, S. Mandel, T. Amit, and M.B. Youdim Neurological mechanisms of green tea polyphenols in Alzheimer's and Parkinson's diseases J. Nutr. Biochem. 15 2004 506 516 (Pubitemid 39209392)
68. M.E. Waltner-Law, X.L. Wang, B.K. Law, R.K. Hall, M. Nawano, and D.K. Granner Epigallocatechin gallate, a constituent of green tea, represses hepatic glucose production J. Biol. Chem. 277 2002 34933 34940
69. S. Wolfram, Y. Wang, and F. Thielecke Anti-obesity effects of green tea: from bedside to bench Mol. Nutr. Food Res. 50 2006 176 187 (Pubitemid 43325659)
70. S.A. Mandel, T. Amit, L. Kalfon, L. Reznichenko, O. Weinreb, and M.B. Youdim Cell signaling pathways and iron chelation in the neurorestorative activity of green tea polyphenols: special reference to epigallocatechin gallate (EGCG) J. Alzheimers Dis. 15 2008 211 222
71. J. Bieschke, J. Russ, R.P. Friedrich, D.E. Ehrnhoefer, H. Wobst, K. Neugebauer, and E.E. Wanker EGCG remodels mature alpha-synuclein and amyloid-beta fibrils and reduces cellular toxicity Proc. Natl. Acad. Sci. U. S. A. 107 2010 7710 7715
72. F. Meng, A. Abedini, A. Plesner, C.B. Verchere, and D.P. Raleigh The flavanol (-)-epigallocatechin 3-gallate inhibits amyloid formation by islet amyloid polypeptide, disaggregates amyloid fibrils, and protects cultured cells against IAPP-induced toxicity Biochemistry 49 2010 8127 8133
73. Y. Porat, A. Abramowitz, and E. Gazit Inhibition of amyloid fibril formation by polyphenols: structural similarity and aromatic interactions as a common inhibition mechanism Chem. Biol. Drug Des. 67 2006 27 37 (Pubitemid 43881385)
74. N. Ferreira, M.J. Saraiva, and M.R. Almeida Epigallocatechin-3-gallate as a potential therapeutic drug for TTR-related amyloidosis: "in vivo" evidence from FAP mice models PLoS One 7 2012 e29933
75. D.E. Ehrnhoefer, J. Bieschke, A. Boeddrich, M. Herbst, L. Masino, R. Lurz, S. Engemann, A. Pastore, and E.E. Wanker EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers Nat. Struct. Mol. Biol. 15 2008 558 566 (Pubitemid 351799141)
76. J.W. Lee, Y.K. Lee, J.O. Ban, T.Y. Ha, Y.P. Yun, S.B. Han, K.W. Oh, and J.T. Hong Green tea (-)-epigallocatechin-3-gallate inhibits beta-amyloid-induced cognitive dysfunction through modification of secretase activity via inhibition of ERK and NF-kappaB pathways in mice J. Nutr. 139 2009 1987 1993
77. K. Rezai-Zadeh, G.W. Arendash, H. Hou, F. Fernandez, M. Jensen, M. Runfeldt, R.D. Shytle, and J. Tan Green tea epigallocatechin-3-gallate (EGCG) reduces beta-amyloid mediated cognitive impairment and modulates tau pathology in Alzheimer transgenic mice Brain Res. 1214 2008 177 187
78. H.H. Chow, I.A. Hakim, D.R. Vining, J.A. Crowell, J. Ranger-Moore, W.M. Chew, C.A. Celaya, S.R. Rodney, Y. Hara, and D.S. Alberts Effects of dosing condition on the oral bioavailability of green tea catechins after single-dose administration of Polyphenon E in healthy individuals Clin. Cancer Res. 11 2005 4627 4633 (Pubitemid 40825654)
79. N. Adachi, S. Tomonaga, T. Tachibana, D.M. Denbow, and M. Furuse (-)-Epigallocatechin gallate attenuates acute stress responses through GABAergic system in the brain Eur. J. Pharmacol. 531 2006 171 175 (Pubitemid 43202231)
80. K. Nakagawa, and T. Miyazawa Absorption and distribution of tea catechin, (-)-epigallocatechin-3-gallate, in the rat J. Nutr. Sci. Vitaminol. (Tokyo) 43 1997 679 684 (Pubitemid 28045726)
81. H. Hatcher, R. Planalp, J. Cho, F.M. Torti, and S.V. Torti Curcumin: from ancient medicine to current clinical trials Cell. Mol. Life Sci. 65 2008 1631 1652
82. T.P. Ng, P.C. Chiam, T. Lee, H.C. Chua, L. Lim, and E.H. Kua Curry consumption and cognitive function in the elderly Am. J. Epidemiol. 164 2006 898 906 (Pubitemid 44627275)
83. K. Ono, K. Hasegawa, H. Naiki, and M. Yamada Curcumin has potent anti-amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro J. Neurosci. Res. 75 2004 742 750 (Pubitemid 38296087)
84. M. Daval, S. Bedrood, T. Gurlo, C.J. Huang, S. Costes, P.C. Butler, and R. Langen The effect of curcumin on human islet amyloid polypeptide misfolding and toxicity Amyloid 17 2010 118 128
85. N. Pandey, J. Strider, W.C. Nolan, S.X. Yan, and J.E. Galvin Curcumin inhibits aggregation of alpha-synuclein Acta Neuropathol. 115 2008 479 489
86. N. Ferreira, M.J. Saraiva, and M.R. Almeida Natural polyphenols as modulators of TTR amyloidogenesis: in vitro and in vivo evidences towards therapy Amyloid 19 Suppl. 1 2012 39 42
87. S.S. Wang, K.N. Liu, and W.H. Lee Effect of curcumin on the amyloid fibrillogenesis of hen egg-white lysozyme Biophys. Chem. 144 2009 78 87
88. Y. Masuda, M. Fukuchi, T. Yatagawa, M. Tada, K. Takeda, K. Irie, K. Akagi, Y. Monobe, T. Imazawa, and K. Takegoshi Solid-state NMR analysis of interaction sites of curcumin and 42-residue amyloid beta-protein fibrils Bioorg. Med. Chem. 19 2011 5967 5974
89. K.Y. Yang, L.C. Lin, T.Y. Tseng, S.C. Wang, and T.H. Tsai Oral bioavailability of curcumin in rat and the herbal analysis from Curcuma longa by LC - MS/MS J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 853 2007 183 189
90. F. Yang, G.P. Lim, A.N. Begum, O.J. Ubeda, M.R. Simmons, S.S. Ambegaokar, P.P. Chen, R. Kayed, C.G. Glabe, S.A. Frautschy, and G.M. Cole Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo J. Biol. Chem. 280 2005 5892 5901 (Pubitemid 40280072)
91. K. Ono, Y. Yoshiike, A. Takashima, K. Hasegawa, H. Naiki, and M. Yamada Potent anti-amyloidogenic and fibril-destabilizing effects of polyphenols in vitro: implications for the prevention and therapeutics of Alzheimer's disease J. Neurochem. 87 2003 172 181 (Pubitemid 37210651)
92. K. Ono, L. Li, Y. Takamura, Y. Yoshiike, L. Zhu, F. Han, X. Mao, T. Ikeda, J. Takasaki, H. Nishijo, A. Takashima, D.B. Teplow, M.G. Zagorski, and M. Yamada Phenolic compounds prevent amyloid beta-protein oligomerization and synaptic dysfunction by site-specific binding J. Biol. Chem. 287 2012 14631 14643
93. T. Hamaguchi, K. Ono, A. Murase, and M. Yamada Phenolic compounds prevent Alzheimer's pathology through different effects on the amyloid-beta aggregation pathway Am. J. Pathol. 175 2009 2557 2565
94. V. Lopez-Miranda, M.L. Soto-Montenegro, G. Vera, E. Herradon, M. Desco, and R. Abalo Resveratrol: a neuroprotective polyphenol in the Mediterranean diet Rev. Neurol. 54 2012 349 356
95. Y. Feng, X.P. Wang, S.G. Yang, Y.J. Wang, X. Zhang, X.T. Du, X.X. Sun, M. Zhao, L. Huang, and R.T. Liu Resveratrol inhibits beta-amyloid oligomeric cytotoxicity but does not prevent oligomer formation Neurotoxicology 30 2009 986 995
96. D. Radovan, N. Opitz, and R. Winter Fluorescence microscopy studies on islet amyloid polypeptide fibrillation at heterogeneous and cellular membrane interfaces and its inhibition by resveratrol FEBS Lett. 583 2009 1439 1445
97. P. Jiang, W. Li, J.E. Shea, and Y. Mu Resveratrol inhibits the formation of multiple-layered beta-sheet oligomers of the human islet amyloid polypeptide segment 22-27 Biophys. J. 100 2011 1550 1558
98. A.R. Ladiwala, J.C. Lin, S.S. Bale, A.M. Marcelino-Cruz, M. Bhattacharya, J.S. Dordick, and P.M. Tessier Resveratrol selectively remodels soluble oligomers and fibrils of amyloid Abeta into off-pathway conformers J. Biol. Chem. 285 2010 24228 24237
99. M. Muzzio, Z. Huang, S.C. Hu, W.D. Johnson, D.L. McCormick, and I.M. Kapetanovic Determination of resveratrol and its sulfate and glucuronide metabolites in plasma by LC-MS/MS and their pharmacokinetics in dogs J. Pharm. Biomed. Anal. 59 2012 201 208
100. J. Tuomilehto, G. Hu, S. Bidel, J. Lindstrom, and P. Jousilahti Coffee consumption and risk of type 2 diabetes mellitus among middle-aged Finnish men and women JAMA 291 2004 1213 1219 (Pubitemid 38541664)
101. M. Monteiro, A. Farah, D. Perrone, L.C. Trugo, and C. Donangelo Chlorogenic acid compounds from coffee are differentially absorbed and metabolized in humans J. Nutr. 137 2007 2196 2201 (Pubitemid 47529576)
102. B. Cheng, X. Liu, H. Gong, L. Huang, H. Chen, X. Zhang, C. Li, M. Yang, B. Ma, L. Jiao, L. Zheng, and K. Huang Coffee components inhibit amyloid formation of human islet amyloid polypeptide in vitro: possible link between coffee consumption and diabetes mellitus J. Agric. Food Chem. 59 2011 13147 13155
103. Y. Porat, Y. Mazor, S. Efrat, and E. Gazit Inhibition of islet amyloid polypeptide fibril formation: a potential role for heteroaromatic interactions Biochemistry 43 2004 14454 14462 (Pubitemid 39491980)
104. M. Levy-Sakin, M. Shreberk, Y. Daniel, and E. Gazit Targeting insulin amyloid assembly by small aromatic molecules: toward rational design of aggregation inhibitors Islets 1 2009 210 215
105. F. Visioli, A. Poli, and C. Gall Antioxidant and other biological activities of phenols from olives and olive oil Med. Res. Rev. 22 2002 65 75 (Pubitemid 34023573)
106. F. Visioli, S. Bellosta, and C. Galli Oleuropein, the bitter principle of olives, enhances nitric oxide production by mouse macrophages Life Sci. 62 1998 541 546 (Pubitemid 28050072)
107. I. Andreadou, E.K. Iliodromitis, E. Mikros, M. Constantinou, A. Agalias, P. Magiatis, A.L. Skaltsounis, E. Kamber, A. Tsantili-Kakoulidou, and D.T. Kremastinos The olive constituent oleuropein exhibits anti-ischemic, antioxidative, and hypolipidemic effects in anesthetized rabbits J. Nutr. 136 2006 2213 2219 (Pubitemid 44156827)
108. S. Rigacci, V. Guidotti, M. Bucciantini, D. Nichino, A. Relini, A. Berti, and M. Stefani Abeta(1-42) aggregates into non-toxic amyloid assemblies in the presence of the natural polyphenol oleuropein aglycon Curr. Alzheimer Res. 8 2011 841 852
109. R. Kayed, E. Head, F. Sarsoza, T. Saing, C.W. Cotman, M. Necula, L. Margol, J. Wu, L. Breydo, J.L. Thompson, S. Rasool, T. Gurlo, P. Butler, and C.G. Glabe Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers Mol. Neurodegener. 2 2007 18
110. S. Rigacci, V. Guidotti, M. Bucciantini, M. Parri, C. Nediani, E. Cerbai, M. Stefani, and A. Berti Oleuropein aglycon prevents cytotoxic amyloid aggregation of human amylin J. Nutr. Biochem. 21 2010 726 735
111. A. Serra, L. Rubio, X. Borras, A. Macia, M.P. Romero, and M.J. Motilva Distribution of olive oil phenolic compounds in rat tissues after administration of a phenolic extract from olive cake Mol. Nutr. Food Res. 56 2012 486 496
112. M. Zhu, S. Rajamani, J. Kaylor, S. Han, F. Zhou, and A.L. Fink The flavonoid baicalein inhibits fibrillation of alpha-synuclein and disaggregates existing fibrils J. Biol. Chem. 279 2004 26846 26857 (Pubitemid 38812518)
113. A.J. Gauci, M. Caruana, A. Giese, C. Scerri, and N. Vassallo Identification of polyphenolic compounds and black tea extract as potent inhibitors of lipid membrane destabilization by Abeta(4)(2) aggregates J. Alzheimers Dis. 27 2011 767 779
114. J.H. Lu, M.T. Ardah, S.S. Durairajan, L.F. Liu, L.X. Xie, W.F. Fong, M.Y. Hasan, J.D. Huang, O.M. El-Agnaf, and M. Li Baicalein inhibits formation of alpha-synuclein oligomers within living cells and prevents Abeta peptide fibrillation and oligomerisation ChemBioChem 12 2011 615 624
115. F. Yin, J. Liu, X. Ji, Y. Wang, J. Zidichouski, and J. Zhang Baicalin prevents the production of hydrogen peroxide and oxidative stress induced by Abeta aggregation in SH-SY5Y cells Neurosci. Lett. 492 2011 76 79
116. S. Tian, G. He, J. Song, S. Wang, W. Xin, D. Zhang, and G. Du Pharmacokinetic study of baicalein after oral administration in monkeys Fitoterapia 83 2012 532 540
117. T. Tarrago, N. Kichik, B. Claasen, R. Prades, M. Teixido, and E. Giralt Baicalin, a prodrug able to reach the CNS, is a prolyl oligopeptidase inhibitor Bioorg. Med. Chem. 16 2008 7516 7524
118. Y. Nakagami, S. Nishimura, T. Murasugi, I. Kaneko, M. Meguro, S. Marumoto, H. Kogen, K. Koyama, and T. Oda A novel beta-sheet breaker, RS-0406, reverses amyloid beta-induced cytotoxicity and impairment of long-term potentiation in vitro Br. J. Pharmacol. 137 2002 676 682 (Pubitemid 35333093)
119. D.M. Walsh, M. Townsend, M.B. Podlisny, G.M. Shankar, J.V. Fadeeva, O. El Agnaf, D.M. Hartley, and D.J. Selkoe Certain inhibitors of synthetic amyloid beta-peptide (Abeta) fibrillogenesis block oligomerization of natural Abeta and thereby rescue long-term potentiation J. Neurosci. 25 2005 2455 2462 (Pubitemid 40365155)
120. E. O'Hare, D.I. Scopes, J.M. Treherne, K. Norwood, D. Spanswick, and E.M. Kim RS-0406 arrests amyloid-beta oligomer-induced behavioural deterioration in vivo Behav. Brain Res. 210 2010 32 37
121. V. Kren, and D. Walterova Silybin and silymarin - new effects and applications Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech. Republic 149 2005 29 41
122. F. Yin, J. Liu, X. Ji, Y. Wang, J. Zidichouski, and J. Zhang Silibinin: a novel inhibitor of Abeta aggregation Neurochem. Int. 58 2011 399 403
123. B. Cheng, H. Gong, X. Li, Y. Sun, X. Zhang, H. Chen, X. Liu, L. Zheng, and K. Huang Silibinin inhibits the toxic aggregation of human islet amyloid polypeptide Biochem. Biophys. Res. Commun. 419 2012 495 499
124. M.K. Tang, and J.T. Zhang Salvianolic acid B inhibits fibril formation and neurotoxicity of amyloid beta-protein in vitro Acta Pharmacol. Sin. 22 2001 380 384
125. B. Cheng, H. Gong, X. Li, Y. Sun, H. Chen, X. Zhang, Q. Wu, L. Zheng, and K. Huang Salvianolic acid B inhibits the amyloid formation of human islet amyloid polypeptide and protects pancreatic beta-cells against cytotoxicity Proteins 81 2013 613 621
126. R. Gujer, D.P. Magnolato, and R. Self Proanthocyanidins and polymeric flavonoids from sorghum Prog. Clin. Biol. Res. 213 1986 159 161
127. R.R. Holt, S.A. Lazarus, M.C. Sullards, Q.Y. Zhu, D.D. Schramm, J.F. Hammerstone, C.G. Fraga, H.H. Schmitz, and C.L. Keen Procyanidin dimer B2 [epicatechin-(4beta-8)-epicatechin] in human plasma after the consumption of a flavanol-rich cocoa Am. J. Clin. Nutr. 76 2002 798 804
128. L. Jiao, X. Zhang, L. Huang, H. Gong, B. Cheng, Y. Sun, Y. Li, Q. Liu, L. Zheng, and K. Huang Proanthocyanidins are the major anti-diabetic components of cinnamon water extract Food Chem. Toxicol. 56 2013 398 405
129. R. Scherzer-Attali, R. Shaltiel-Karyo, Y.H. Adalist, D. Segal, and E. Gazit Generic inhibition of amyloidogenic proteins by two naphthoquinone- tryptophan hybrid molecules Proteins 80 2012 1962 1973
130. R. Scherzer-Attali, D. Farfara, I. Cooper, A. Levin, T. Ben-Romano, D. Trudler, M. Vientrov, R. Shaltiel-Karyo, D.E. Shalev, N. Segev-Amzaleg, E. Gazit, D. Segal, and D. Frenkel Naphthoquinone-tyrptophan reduces neurotoxic Abeta*56 levels and improves cognition in Alzheimer's disease animal model Neurobiol. Dis. 46 2012 663 672
131. P. Anand, B. Singh, and N. Singh A review on coumarins as acetylcholinesterase inhibitors for Alzheimer's disease Bioorg. Med. Chem. 20 2012 1175 1180
132. D.D. Soto-Ortega, B.P. Murphy, F.J. Gonzalez-Velasquez, K.A. Wilson, F. Xie, Q. Wang, and M.A. Moss Inhibition of amyloid-beta aggregation by coumarin analogs can be manipulated by functionalization of the aromatic center Bioorg. Med. Chem. 19 2011 2596 2602
133. J. McLaurin, R. Golomb, A. Jurewicz, J.P. Antel, and P.E. Fraser Inositol stereoisomers stabilize an oligomeric aggregate of Alzheimer amyloid beta peptide and inhibit abeta-induced toxicity J. Biol. Chem. 275 2000 18495 18502 (Pubitemid 30414810)
134. C.A. Hawkes, L.H. Deng, J.E. Shaw, M. Nitz, and J. McLaurin Small molecule beta-amyloid inhibitors that stabilize protofibrillar structures in vitro improve cognition and pathology in a mouse model of Alzheimer's disease Eur. J. Neurosci. 31 2010 203 213
135. G. Sebastiani, P. Krzywkowski, S. Dudal, M. Yu, J. Paquette, D. Malo, F. Gervais, and P. Tremblay Mapping genetic modulators of amyloid plaque deposition in TgCRND8 transgenic mice Hum. Mol. Genet. 15 2006 2313 2323 (Pubitemid 44288677)
136. R. Spector Myo-inositol transport through the blood-brain barrier Neurochem. Res. 13 1988 785 787
137. I. Granic, C. Nyakas, P.G. Luiten, U.L. Eisel, L.G. Halmy, G. Gross, H. Schoemaker, A. Moller, and V. Nimmrich Calpain inhibition prevents amyloid-beta-induced neurodegeneration and associated behavioral dysfunction in rats Neuropharmacology 59 2010 334 342
138. R. Sterniczuk, R.H. Dyck, F.M. Laferla, and M.C. Antle Characterization of the 3 × Tg-AD mouse model of Alzheimer's disease: part 1. Circadian changes Brain Res. 1348 2010 139 148
139. R. Medeiros, M. Kitazawa, M.A. Chabrier, D. Cheng, D. Baglietto-Vargas, A. Kling, A. Moeller, K.N. Green, and F.M. Laferla Calpain inhibitor A-705253 mitigates Alzheimer's disease-like pathology and cognitive decline in aged 3 × TgAD mice Am. J. Pathol. 181 2012 616 625
140. W. Zhao, J. Wang, L. Ho, K. Ono, D.B. Teplow, and G.M. Pasinetti Identification of antihypertensive drugs which inhibit amyloid-beta protein oligomerization J. Alzheimers Dis. 16 2009 49 57
141. G. Said, S. Grippon, and P. Kirkpatrick Tafamidis Nat. Rev. Drug Discov. 11 2012 185 186
142. J. de Lartigue Tafamidis for transthyretin amyloidosis Drugs Today (Barc) 48 2012 331 337
143. C.E. Bulawa, S. Connelly, M. Devit, L. Wang, C. Weigel, J.A. Fleming, J. Packman, E.T. Powers, R.L. Wiseman, T.R. Foss, I.A. Wilson, J.W. Kelly, and R. Labaudiniere Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade Proc. Natl. Acad. Sci. U. S. A. 109 2012 9629 9634
144. A.F. McKoy, J. Chen, T. Schupbach, and M.H. Hecht A novel inhibitor of amyloid beta (Abeta) peptide aggregation: from high throughput screening to efficacy in an animal model of Alzheimer disease J. Biol. Chem. 287 2012 38992 39000
145. A.A. Reinke, and J.E. Gestwicki Structure-activity relationships of amyloid beta-aggregation inhibitors based on curcumin: influence of linker length and flexibility Chem. Biol. Drug Des. 70 2007 206 215 (Pubitemid 47305405)
146. R.A. Orlando, A.M. Gonzales, R.E. Royer, L.M. Deck, and D.L. Vander Jagt A chemical analog of curcumin as an improved inhibitor of amyloid Abeta oligomerization PLoS One 7 2012 e31869
147. P. Cao, and D.P. Raleigh Analysis of the inhibition and remodeling of islet amyloid polypeptide amyloid fibers by flavanols Biochemistry 51 2012 2670 2683
148. H. Noor, P. Cao, and D.P. Raleigh Morin hydrate inhibits amyloid formation by islet amyloid polypeptide and disaggregates amyloid fibers Protein Sci. 21 2012 373 382
149. I. Horvath, C.F. Weise, E.K. Andersson, E. Chorell, M. Sellstedt, C. Bengtsson, A. Olofsson, S.J. Hultgren, M. Chapman, M. Wolf-Watz, F. Almqvist, and P. Wittung-Stafshede Mechanisms of protein oligomerization: inhibitor of functional amyloids templates alpha-synuclein fibrillation J. Am. Chem. Soc. 134 2012 3439 3444
150. X. Zhang, B. Cheng, H. Gong, C. Li, H. Chen, L. Zheng, and K. Huang Porcine islet amyloid polypeptide fragments are refractory to amyloid formation FEBS Lett. 585 2011 71 77
151. C.J. Pike, A.J. Walencewicz-Wasserman, J. Kosmoski, D.H. Cribbs, C.G. Glabe, and C.W. Cotman Structure-activity analyses of beta-amyloid peptides: contributions of the beta 25-35 region to aggregation and neurotoxicity J. Neurochem. 64 1995 253 265
152. T.L. Lowe, A. Strzelec, L.L. Kiessling, and R.M. Murphy Structure-function relationships for inhibitors of beta-amyloid toxicity containing the recognition sequence KLVFF Biochemistry 40 2001 7882 7889 (Pubitemid 32622980)
153. C. Soto, M.S. Kindy, M. Baumann, and B. Frangione Inhibition of Alzheimer's amyloidosis by peptides that prevent beta-sheet conformation Biochem. Biophys. Res. Commun. 226 1996 672 680 (Pubitemid 26348532)
154. C. Soto, E.M. Sigurdsson, L. Morelli, R.A. Kumar, E.M. Castano, and B. Frangione Beta-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy Nat. Med. 4 1998 822 826 (Pubitemid 28331024)
155. B. Permanne, C. Adessi, G.P. Saborio, S. Fraga, M.J. Frossard, J. Van Dorpe, I. Dewachter, W.A. Banks, F. Van Leuven, and C. Soto Reduction of amyloid load and cerebral damage in a transgenic mouse model of Alzheimer's disease by treatment with a beta-sheet breaker peptide FASEB J. 16 2002 860 862
156. J.F. Poduslo, G.L. Curran, A. Kumar, B. Frangione, and C. Soto Beta-sheet breaker peptide inhibitor of Alzheimer's amyloidogenesis with increased blood-brain barrier permeability and resistance to proteolytic degradation in plasma J. Neurobiol. 39 1999 371 382 (Pubitemid 29239200)
157. J. Chabry, B. Caughey, and B. Chesebro Specific inhibition of in vitro formation of protease-resistant prion protein by synthetic peptides J. Biol. Chem. 273 1998 13203 13207 (Pubitemid 28246891)
158. O.M. El-Agnaf, K.E. Paleologou, B. Greer, A.M. Abogrein, J.E. King, S.A. Salem, N.J. Fullwood, F.E. Benson, R. Hewitt, K.J. Ford, F.L. Martin, P. Harriott, M.R. Cookson, and D. Allsop A strategy for designing inhibitors of alpha-synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders FASEB J. 18 2004 1315 1317 (Pubitemid 39561588)
159. L.A. Scrocchi, Y. Chen, S. Waschuk, F. Wang, S. Cheung, A.A. Darabie, J. McLaurin, and P.E. Fraser Design of peptide-based inhibitors of human islet amyloid polypeptide fibrillogenesis J. Mol. Biol. 318 2002 697 706 (Pubitemid 34729362)
160. Y. Nagai, T. Tucker, H. Ren, D.J. Kenan, B.S. Henderson, J.D. Keene, W.J. Strittmatter, and J.R. Burke Inhibition of polyglutamine protein aggregation and cell death by novel peptides identified by phage display screening J. Biol. Chem. 275 2000 10437 10442 (Pubitemid 30202104)
161. T.J. Gibson, and R.M. Murphy Inhibition of insulin fibrillogenesis with targeted peptides Protein Sci. 15 2006 1133 1141
162. H.A. Popiel, T. Takeuchi, J.R. Burke, W.J. Strittmatter, T. Toda, K. Wada, and Y. Nagai Inhibition of protein misfolding/aggregation using polyglutamine binding peptide QBP1 as a therapy for the polyglutamine diseases Neurotherapeutics 10 2013 440 446
163. I. Saraogi, J.A. Hebda, J. Becerril, L.A. Estroff, A.D. Miranker, and A.D. Hamilton Synthetic alpha-helix mimetics as agonists and antagonists of islet amyloid polypeptide aggregation Angew. Chem. Int. Ed. Engl. 49 2010 736 739
164. S. Kumar, and A.D. Miranker A foldamer approach to targeting membrane bound helical states of islet amyloid polypeptide Chem. Commun. (Camb) 49 2013 4749 4751
165. P. Manavalan, and F.A. Momany Conformational energy studies on N-methylated analogs of thyrotropin releasing hormone, enkephalin, and luteinizing hormone-releasing hormone Biopolymers 19 1980 1943 1973 (Pubitemid 11172304)
166. E. Hughes, R.M. Burke, and A.J. Doig Inhibition of toxicity in the beta-amyloid peptide fragment beta-(25-35) using N-methylated derivatives: a general strategy to prevent amyloid formation J. Biol. Chem. 275 2000 25109 25115
167. A.J.D. Hozefa Amijee, Edmund Nerou, David I.C. Scopes, and J. Mark Treherne β-amyloid aggregation inhibitors for the treatment of Alzheimer's disease Alzheimers Dement. 4 2008 P2 295
168. L.M. Yan, M. Tatarek-Nossol, A. Velkova, A. Kazantzis, and A. Kapurniotu Design of a mimic of nonamyloidogenic and bioactive human islet amyloid polypeptide (IAPP) as nanomolar affinity inhibitor of IAPP cytotoxic fibrillogenesis Proc. Natl. Acad. Sci. U. S. A. 103 2006 2046 2051 (Pubitemid 43271620)
169. D.J. Selkoe Alzheimer's disease: genes, proteins, and therapy Physiol. Rev. 81 2001 741 766 (Pubitemid 32267077)
170. S.A. Sievers, J. Karanicolas, H.W. Chang, A. Zhao, L. Jiang, O. Zirafi, J.T. Stevens, J. Munch, D. Baker, and D. Eisenberg Structure-based design of non-natural amino-acid inhibitors of amyloid fibril formation Nature 475 2011 96 100
171. B. Solomon, R. Koppel, E. Hanan, and T. Katzav Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide Proc. Natl. Acad. Sci. U. S. A. 93 1996 452 455 (Pubitemid 26038175)
172. M. Dumoulin, A.M. Last, A. Desmyter, K. Decanniere, D. Canet, G. Larsson, A. Spencer, D.B. Archer, J. Sasse, S. Muyldermans, L. Wyns, C. Redfield, A. Matagne, C.V. Robinson, and C.M. Dobson A camelid antibody fragment inhibits the formation of amyloid fibrils by human lysozyme Nature 424 2003 783 788 (Pubitemid 37021708)
173. T. Nasstrom, S. Goncalves, C. Sahlin, E. Nordstrom, V. Screpanti Sundquist, L. Lannfelt, J. Bergstrom, T.F. Outeiro, and M. Ingelsson Antibodies against alpha-synuclein reduce oligomerization in living cells PLoS One 6 2011 e27230
174. G. Habicht, C. Haupt, R.P. Friedrich, P. Hortschansky, C. Sachse, J. Meinhardt, K. Wieligmann, G.P. Gellermann, M. Brodhun, J. Gotz, K.J. Halbhuber, C. Rocken, U. Horn, and M. Fandrich Directed selection of a conformational antibody domain that prevents mature amyloid fibril formation by stabilizing Abeta protofibrils Proc. Natl. Acad. Sci. U. S. A. 104 2007 19232 19237
175. R. Kayed, E. Head, J.L. Thompson, T.M. McIntire, S.C. Milton, C.W. Cotman, and C.G. Glabe Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis Science 300 2003 486 489 (Pubitemid 36444329)
176. D. Kaufer, and S. Gandy APOE {epsilon}4 and bapineuzumab: infusing pharmacogenomics into Alzheimer disease therapeutics Neurology 73 2009 2052 2053
177. E.R. Siemers, S. Friedrich, R.A. Dean, C.R. Gonzales, M.R. Farlow, S.M. Paul, and R.B. Demattos Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease Clin. Neuropharmacol. 33 2010 67 73
178. S.L. La Porte, S.S. Bollini, T.A. Lanz, Y.N. Abdiche, A.S. Rusnak, W.H. Ho, D. Kobayashi, O. Harrabi, D. Pappas, E.W. Mina, A.J. Milici, T.T. Kawabe, K. Bales, J.C. Lin, and J. Pons Structural basis of C-terminal beta-amyloid peptide binding by the antibody ponezumab for the treatment of Alzheimer's disease J. Mol. Biol. 421 2012 525 536
179. S. Ostrowitzki, D. Deptula, L. Thurfjell, F. Barkhof, B. Bohrmann, D.J. Brooks, W.E. Klunk, E. Ashford, K. Yoo, Z.X. Xu, H. Loetscher, and L. Santarelli Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab Arch. Neurol. 69 2012 198 207
180. F. Khorassani, and O. Hilas Bapineuzumab, an investigational agent for Alzheimer's disease P. T. 38 2013 89 91
181. J.W. Landen, Q. Zhao, S. Cohen, M. Borrie, M. Woodward, C.B. Billing Jr., K. Bales, C. Alvey, F. McCush, J. Yang, J.W. Kupiec, and M.M. Bednar Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study Clin. Neuropharmacol. 36 2013 14 23
182. J.K. Atwal, Y. Chen, C. Chiu, D.L. Mortensen, W.J. Meilandt, Y. Liu, C.E. Heise, K. Hoyte, W. Luk, Y. Lu, K. Peng, P. Wu, L. Rouge, Y. Zhang, R.A. Lazarus, K. Scearce-Levie, W. Wang, Y. Wu, M. Tessier-Lavigne, and R.J. Watts A therapeutic antibody targeting BACE1 inhibits amyloid-beta production in vivo Sci. Transl. Med. 3 2011 84ra43
183. B.F. Shaw, and J.S. Valentine How do ALS-associated mutations in superoxide dismutase 1 promote aggregation of the protein? Trends Biochem. Sci. 32 2007 78 85 (Pubitemid 46199198)
184. M. Reches, and E. Gazit Amyloidogenic hexapeptide fragment of medin: homology to functional islet amyloid polypeptide fragments Amyloid 11 2004 81 89 (Pubitemid 39222404)
185. M. Reches, Y. Porat, and E. Gazit Amyloid fibril formation by pentapeptide and tetrapeptide fragments of human calcitonin J. Biol. Chem. 277 2002 35475 35480
186. G.T. Westermark, U. Engstrom, and P. Westermark The N-terminal segment of protein AA determines its fibrillogenic property Biochem. Biophys. Res. Commun. 182 1992 27 33
187. Q. Nie, X.G. Du, and M.Y. Geng Small molecule inhibitors of amyloid beta peptide aggregation as a potential therapeutic strategy for Alzheimer's disease Acta Pharmacol. Sin. 32 2011 545 551